Examkin

Question

Difficulty: Very hardDiagnostic and Screening Test Performance

A national health ministry implements a two-step diagnostic protocol for a newly identified infectious pathogen. The protocol dictates that all individuals in a high-risk region first undergo a rapid biomarker assay. Only those who test positive on this initial screening proceed to a highly specific nucleic acid amplification test (NAAT) for definitive diagnosis. After two months of implementation, laboratory bottlenecks prompt the ministry to alter the diagnostic cutoff for the rapid biomarker assay, requiring a significantly higher biomarker concentration to trigger a "positive" result. Assuming the true prevalence of the infection in the region remains constant, which of the following is the most likely consequence of this policy change on the testing protocol's performance metrics?

  1. The negative predictive value of the nucleic acid amplification test will decrease.Answer
  2. B
    The pre-test probability for the nucleic acid amplification test will decrease.
  3. C
    The positive predictive value of the rapid biomarker assay will decrease.
  4. D
    The negative predictive value of the rapid biomarker assay will increase.
  5. E
    The overall false-negative rate of the two-step protocol will decrease.

Answer

The negative predictive value of the nucleic acid amplification test will decrease.
Raising the diagnostic cutoff for the rapid biomarker assay makes the test more stringent, which increases its specificity (fewer false positives) and decreases its sensitivity (more false negatives). In a screening protocol, the decrease in false positives increases the positive predictive value (PPV) of the rapid assay. Because only patients who test positive on the rapid assay proceed to the nucleic acid amplification test (NAAT), the PPV of the rapid assay serves as the pre-test probability (prevalence) for the NAAT. An increase in the pre-test probability of a disease mathematically results in a decreased negative predictive value (NPV) for any subsequent test, as a negative result is less likely to be a true negative when the disease is more common in the tested population.

Step-by-Step Solution

1
Determine the effect of a higher diagnostic cutoff on the rapid biomarker assay's sensitivity and specificity.
Sensitivity decreases and specificity increases.
A higher diagnostic threshold requires more biomarker to be present to trigger a positive result, meaning fewer true cases will be detected (lower sensitivity) and fewer healthy individuals will be incorrectly flagged (higher specificity).
2
Determine the effect of these changes on the positive predictive value (PPV) of the rapid biomarker assay.
The PPV of the rapid biomarker assay increases.
The increase in specificity significantly reduces the number of false positives. In screening populations, reducing false positives is the primary driver for increasing the positive predictive value.
3
Identify the pre-test probability for the subsequent nucleic acid amplification test (NAAT).
The pre-test probability for the NAAT is equal to the PPV of the rapid biomarker assay.
Because only patients who test positive on the rapid assay proceed to the NAAT, the prevalence of disease in this newly tested subgroup is exactly the PPV of the first test.
4
Determine the effect of an increased pre-test probability on the NAAT's negative predictive value (NPV).
The NPV of the NAAT decreases.
When disease prevalence (pre-test probability) increases, a negative test result is less reliable because there are more true cases in the population that could yield false negatives.

Key Concept

In a sequential testing protocol, the positive predictive value of the initial screening test becomes the pre-test probability for the confirmatory test. Raising a test's cutoff increases its specificity and PPV, which consequently decreases the NPV of the subsequent confirmatory test.
Rate this question

Topics

Diagnostic and Screening Test Performance

More questions from this topic